Jason Slakter, MD, is a seasoned biotechnology entrepreneur and internationally recognized retinal disease specialist with over 35 years of experience in clinical practice. He is a partner of Vitreous Retina Macula Consultants of New York and is a Clinical Professor of Ophthalmology at New York University School of Medicine.
Dr. Slakter is also the founder of the Digital Angiography Reading Center (DARC), one of the largest centers for ocular image evaluation for clinical trials of posterior segment disease with over 1,700 certified clinical sites in over 75 countries worldwide, which was sold to WorldCare Clinical in 2021 and is now part of Voiant Clinical. In his role with DARC and now Voiant, he has served as a key adviser to most of the global pharmaceutical companies conducting clinical research for ocular diseases, providing support to clinical development activities as well as regulatory submissions. He was previously Chief Executive Officer of Ohr Pharmaceuticals, a publicly traded company developing treatments for macular disease as well as Chief Medical Officer of Potentia Pharmaceuticals, which was acquired by Novartis and later formed the basis of Apellis Pharmaceuticals.
He has been the recipient of many professional awards including the Macula Society’s Richard and Hinda Rosenthal Award, the Helen Keller Manhattan League Award, and Life Achievement Honor Award from the American Academy of Ophthalmology. Dr. Slakter serves on the scientific advisory board of multiple companies and has published more than 100 papers and book chapters.